Prostate cancer aggressiveness generally correlates with an intense uptake of the PSMA on preoperative PSMA PET/CT; however, there is a subpopulation of patients with clinically significant cancer and aggressive characteristics that show only weak PSMA uptake. The gene discussed is FOLH1; the disease is prostate cancer.